Translational Medicine 2015: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An early phase IIa trial report - Wei-Dong Han - Chinese PLA General Hospital
Patients with relapsed or refractory Non-Hodgkin lymphoma (NHL) make sure a dismal prediction. Chimeric antigen receptor (CAR) modified T cells targeting CD20 have shown activity in clinical test phase ... administering…

